Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Launched by AIO-STUDIEN-GGMBH · Dec 3, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at how well different tests can help understand and treat patients with lung cancer, specifically focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The goal is to see how these tests can predict treatment outcomes and improve care for patients in Germany. The study is currently recruiting participants aged 18 and older who have been diagnosed with lung cancer, whether they are just starting treatment or receiving supportive care.

To be eligible, participants need to have a confirmed diagnosis of NSCLC or SCLC and must agree to take part in the study within a specific time frame after starting treatment or being diagnosed. If you join the trial, you will help researchers gather important information that could lead to better treatments for lung cancer in the future. There are no specific exclusions for this study, meaning most patients with a lung cancer diagnosis may have the opportunity to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients who meet all of the following criteria are eligible for the project:
• • Age ≥ 18 years
• • Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
• Main project (Metatstatic NSCLC):
• • Confirmed non-small cell lung cancer (NSCLC)
• • Informed consent no later than four weeks after start of first-line systemic treatment or no later than four weeks after diagnosis for patients receiving "best supportive care only"
• • Stage IV, or stage IIIB/C (UICC8) if patient is ineligible for curative surgery and/or radiochemotherapy
• • Systemic therapy or best supportive care
• Satellite Stage I/II/III (NSCLC):
• • Confirmed non-small cell lung cancer (NSCLC)
• • Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or no later than four weeks after diagnosis for patients receiving "best supportive care only" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)
• • Stage I, Stage II, stage IIIA, or stage IIIB/C (UICC8)
• • Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care
• • Satellite SCLC
• • Confirmed Small cell lung cancer (SCLC)
• • Informed consent no later than four weeks after start of first anti-tumor treatment or no later than four weeks after diagnosis for patients receiving "best supportive care only" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)
• • Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care
• Exclusion Criteria:
• • none